Healthcare & Life Sciences

Oxford Brain Diagnostics

activeseries-a
series-a
Stage
1
Investors

About

Oxford Brain Diagnostics develops Cortical Disarray Measurement (CDM) technology that analyzes MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases such as Alzheimer's and Parkinson's.

Explore Oxford Brain Diagnostics's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.